Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.64 |
| ▸ | CTSL | P07711 | 6/20 | 0.64 |
| ▸ | CTSK | P43235 | 6/20 | 0.64 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16227398 | 0.87 | CTSS (0.85) | CTSSCTSLCTSKTYRO3STAT6 | |
| SCHEMBL16227482 | 0.82 | NPC1 (0.51) | KMT2ASMN1; SMN2 | |
| SCHEMBL16227467 | 0.80 | CTSS (0.59) | CTSSCTSLCTSKKMT2ASMN1; SMN2 | |
| SCHEMBL16231082 | 0.80 | CTSS (0.74) | CTSSCTSLCTSKTYRO3STAT6 | |
| SCHEMBL16232238 | 0.78 | CTSS (1.00) | CTSSCTSLCTSKTYRO3 | |
| SCHEMBL16231092 | 0.77 | CTSL (0.77) | CTSSCTSLCTSKTYRO3STAT6 | |
| SCHEMBL16231098 | 0.75 | CTSS (0.62) | CTSSCTSLCTSKTYRO3STAT6 | |
| SCHEMBL16232056 | 0.74 | CTSS (1.00) | CTSSCTSLCTSKTYRO3 | |
| SCHEMBL16227081 | 0.73 | CTSS (0.84) | CTSSCTSLCTSKTYRO3STAT6 | |
| SCHEMBL16231102 | 0.73 | CTSL (0.79) | CTSSCTSLCTSKTYRO3SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336503-A1 | RADIOLABELED BIOMARKERS FOR OSTEOCLAST ACTIVATION AND RELATED METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336503-A1 | RADIOLABELED BIOMARKERS FOR OSTEOCLAST ACTIVATION AND RELATED METHODS THEREOF | CTSK, CTSF, CTSB | CTSS 7/4885CTSL 11/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.